

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Gennova Biopharma sells mRNA biz to Immunoscript Life Science for Rs 139.5 Cr

19 July 2026 | News

Transfer of mRNA business to a company focused on precision immunology and advanced therapeutic development



Emcure Pharmaceuticals has announced that its subsidiary, Genova Biopharmaceuticals, has entered into a Business Transfer Agreement (BTA) to divest its mRNA business to Immunoscrypt Life Science. The transaction will be executed for a lump sum cash consideration of Rs 139.5 crore.

This strategic move allows Genova to reorganise operations and focus on core areas such as research and development, manufacturing, and marketing of biotechnology-based products, including biosimilars and adjacent therapeutic platforms. During FY2025-26, Genova reported a turnover of Rs 491.7 crore.

The buyer, Immunoscrypt Life Science, is a Pune-based company promoted by Dr Sanjay Singh, formerly a director of Genova. The company is focused on precision immunology, combining biological engineering, artificial intelligence and scalable biomanufacturing to develop next-generation vaccines and advanced therapeutics. Immunoscrypt was incorporated in April 2026 and is not part of Emcure's promoter or group companies.